FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum
DCAL Share Price Target
Dishman Carbogen Amcis Ltd.
Sector: Pharmaceuticals and health care
Sector: Pharmaceuticals and health care
DCAL Share Price *
125 +1.4 (1.13%)
* (quote may be delayed)
DCAL Share Price Forecast - Consensus
| No. of reports in last year | 8 |
| No. of analysts | 4 |
| Average Consensus Forecast | 344.13 |
| Consensus Potential | 61.93% |
DCAL Share Price Target - Broker Reports - 2019
Nirmal Bang
25-Oct-19
Price @ Call: 118.35
Target: 185
BUY
We have rolled over our valuation and shift from EV/EBITDA based valuation methodology to P/E based. We have adjusted our EPS for IND AS 116 Impact and have lowered our growth estimates for CRAMs business. We assign a 10x PE multiple to September 2021 earnings to arrive at a target price of Rs185 (from Rs369 earlier).
HDFC Securities
20-Sep-19
Price @ Call: 172.35
Target: 350
BUY
We remain constructive on DCAL owing to strong visibility on its order book, 15+ late phase 3 molecules, expanded development capacity, ability to work on new molecules like ADCs, and favorable currency. Improvement in BS driven by reduced debt and working capital release would be one of the important parameters to drive re-rating of the stock. At CMP, the stock is trading at 10.1/7.8 FY19/20E, a ~60% discount to peers like Divi’s Labs. Maintain BUY with a TP of Rs 350 (15x FY21E EPS).
HDFC Securities
19-Aug-19
Price @ Call: 178
Target: 355
BUY
We maintain a BUY on DCAL following a disappointing quarter. Our TP is revised to Rs 355 (15x FY21E EPS) with a 5% cut to FY21E EPS (higher depreciation expectation).
Nirmal Bang
16-Aug-19
Price @ Call: 178.12
Target: 344
BUY
Despite a weak quarter, the company has maintained its full year guidance of 10% growth in revenue and EBITDA margin in the range of 26%-27%. Our forecasts assume revenue and EBITDA margin slightly above the guidance range. However, considering the market conditions, we lower our target valuation multiple on DCAL to 9x EV/EBITDA from 11x EV/EBITDA and arrive at a target price (TP) of Rs344.
AnandRathi
20-May-19
Price @ Call: 215.75
Target: 390
BUY
We expect revenue and PAT CAGRs over FY19-21 of respectively ~12% and ~19%. We maintain a Buy, with a higher target of Rs 390 based on FY21e EPS.
HDFC Securities
28-Jan-19
Price @ Call: 216.25
Target: 380
BUY
Nirmal Bang
28-Jan-19
Price @ Call: 216.25
Target: 429
BUY
Karvy Stock Broking
28-Jan-19
Price @ Call: 216.25
Target: 320
BUY
DCAL Share Price Target - Broker Reports - 2018
HDFC Securities
7-Dec-18
Price @ Call: 237.12
Target: 355
BUY
HDFC Securities
1-Oct-18
Price @ Call: 236.54
Target: 415
BUY
AnandRathi
31-Jul-18
Price @ Call: 261.3
Target: 380
BUY
DCAL Share Price Target - Broker Reports - 2017
HDFC Securities
26-Dec-17
Price @ Call: 317.56
Target: 435
BUY
Nirmal Bang
13-Nov-17
Price @ Call: 293.75
Target: 410
BUY